DE60234713D1 - Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind - Google Patents
Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sindInfo
- Publication number
- DE60234713D1 DE60234713D1 DE60234713T DE60234713T DE60234713D1 DE 60234713 D1 DE60234713 D1 DE 60234713D1 DE 60234713 T DE60234713 T DE 60234713T DE 60234713 T DE60234713 T DE 60234713T DE 60234713 D1 DE60234713 D1 DE 60234713D1
- Authority
- DE
- Germany
- Prior art keywords
- par4
- apoptosis
- date
- cell
- control
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34199701P | 2001-12-18 | 2001-12-18 | |
PCT/EP2002/014027 WO2003051917A2 (en) | 2001-12-18 | 2002-12-10 | Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60234713D1 true DE60234713D1 (de) | 2010-01-21 |
Family
ID=23339898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60234713T Expired - Lifetime DE60234713D1 (de) | 2001-12-18 | 2002-12-10 | Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind |
Country Status (9)
Country | Link |
---|---|
US (2) | US7572886B2 (de) |
EP (1) | EP1458754B1 (de) |
JP (2) | JP2005527191A (de) |
AT (1) | ATE451387T1 (de) |
AU (1) | AU2002361385B2 (de) |
CA (1) | CA2471777A1 (de) |
DE (1) | DE60234713D1 (de) |
ES (1) | ES2337989T3 (de) |
WO (1) | WO2003051917A2 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7858297B2 (en) | 2001-12-18 | 2010-12-28 | Centre National De La Recherche Scientifique Cnrs | Chemokine-binding protein and methods of use |
AU2002361385B2 (en) | 2001-12-18 | 2009-11-19 | Centre National De La Recherche Scientifique Cnrs | Novel death associated proteins of the THAP family and related Par4 pathways involved in apoptosis control |
CA2477953A1 (en) * | 2002-03-01 | 2003-09-12 | Roger Williams Hospital | Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer |
US20050004008A1 (en) * | 2002-03-01 | 2005-01-06 | Frackelton A. Raymond | SHC proteins as therapeutic targets in proliferative diseases |
CA2507924A1 (en) * | 2002-12-10 | 2004-07-01 | Endocube Sas | Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation |
EP2336779B1 (de) * | 2004-02-19 | 2013-07-31 | Yale University | Kit für die Identifizierung von Ovarial-Krebsprotein-Biomarkern unter Verwendung von Proteomtechniken |
JP2008502582A (ja) * | 2004-06-18 | 2008-01-31 | アンドキューブ ソシエタ パー アクシオン シンプリフィー | ケモカイン結合タンパク質およびその使用方法 |
US20060094059A1 (en) * | 2004-09-22 | 2006-05-04 | Odyssey Thera, Inc. | Methods for identifying new drug leads and new therapeutic uses for known drugs |
EP1946117B1 (de) * | 2005-11-11 | 2011-08-24 | Roger Williams Hospital | P66-shc als prädiktiver marker bei der krebsbehandlung |
US8568980B2 (en) * | 2009-01-27 | 2013-10-29 | Mount Sinai School Of Medicine | Nucleic acids, methods and kits for the diagnosis of DYT6 primary torsion dystonia |
JP5719443B2 (ja) * | 2010-09-26 | 2015-05-20 | ダ・ユー・エンタープライジズ、エルエルシー | 組換え巨大分子製造方法 |
EA201590916A1 (ru) | 2012-11-09 | 2016-02-29 | Корнэлл Юниверсити | Низкомолекулярные ингибиторы malt1 |
US11730750B2 (en) | 2020-02-17 | 2023-08-22 | University Of Kentucky Research Foundation | Drugs for GRP78 cell surface translocation and Par-4 secretion |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US82206A (en) * | 1868-09-15 | William chesley | ||
US4873191A (en) * | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4870009A (en) * | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8311018D0 (en) * | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
US4736866A (en) * | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (de) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimäre Rezeptoren durch Verbindung und Expression von DNS |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0273085A1 (de) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | Verfahren zur Einführung fremder Nukleinsäuren in eukaryotische Zellen |
ATE114723T1 (de) | 1987-03-02 | 1994-12-15 | Enzon Lab Inc | Organismus als träger für ''single chain antibody domain (scad)''. |
US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
EP0436597B1 (de) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
IT1227907B (it) * | 1988-12-23 | 1991-05-14 | Eniricerche S P A Milano Sclav | Procedimento per la sintesi di peptidi retro-inversi e nuovi intermediin tale procedimento |
US5096815A (en) * | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5198346A (en) * | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5424186A (en) * | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
US5073627A (en) * | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
EP0585287B1 (de) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Verfahren zur herstellung von spezifischen bindungspaargliedern |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0564531B1 (de) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
EP1046421B8 (de) | 1990-12-06 | 2006-01-11 | Affymetrix, Inc. (a Delaware Corporation) | Verfahren und Reagenzien für immobilisierten Polymersynthese in sehr grossem Masstab |
US5270181A (en) * | 1991-02-06 | 1993-12-14 | Genetics Institute, Inc. | Peptide and protein fusions to thioredoxin and thioredoxin-like molecules |
US5292646A (en) * | 1991-02-06 | 1994-03-08 | Genetics Institute, Inc. | Peptide and protein fusions to thioredoxin and thioredoxin-like molecules |
AU1545692A (en) | 1991-03-01 | 1992-10-06 | Protein Engineering Corporation | Process for the development of binding mini-proteins |
JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
DK0606217T4 (da) * | 1991-06-27 | 2009-03-30 | Bristol Myers Squibb Co | CTL4-receptor, fusionsproteiner indeholdende den samt anvendelse deraf |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
US5219089A (en) * | 1992-03-12 | 1993-06-15 | Chapco Carton Company | Non-corrugated cardboard box construction |
AU678787B2 (en) | 1992-10-23 | 1997-06-12 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
ATE256738T1 (de) | 1992-10-30 | 2004-01-15 | Gen Hospital Corp | Ein neues zellzyklus kontrollprotein |
CA2148484A1 (en) * | 1992-11-13 | 1994-05-26 | Stewart Lyman | Novel cytokine designated elk ligand |
US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
FR2707296B1 (fr) | 1993-07-09 | 1995-09-29 | Genset Sa | Procédé de synthèse d'acides nucléiques sur support solide et composés utiles notamment comme support solide dans ledit procédé. |
US5457035A (en) * | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
CA2139065A1 (en) * | 1994-12-23 | 1996-06-24 | Eugenia Wang | Apoptosis specific tp30 protein |
US6221615B1 (en) * | 1995-05-12 | 2001-04-24 | Apoptosis Technology, Inc. | Peptides and compositions which modulate apoptosis |
US5897999A (en) * | 1996-03-22 | 1999-04-27 | The Johns Hopkins University | Cancer drug screen based on cell cycle uncoupling |
WO1997047321A1 (en) * | 1996-06-14 | 1997-12-18 | The Johns Hopkins University School Of Medicine | Use of chimeric vaccinia virus complement control proteins to inhibit complement |
US6242569B1 (en) * | 1997-02-05 | 2001-06-05 | Tularik, Inc. | Regulators of apoptosis |
US6191269B1 (en) * | 1997-05-30 | 2001-02-20 | The Regents Of The University Of California | Selective induction of cell death by delivery of amino-terminal interleukin-1-α pro-piece polypeptide |
US6340740B1 (en) * | 1997-08-26 | 2002-01-22 | Thomas Jefferson University | Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use |
WO1999031236A2 (en) * | 1997-12-17 | 1999-06-24 | Genset | EXTENDED cDNAs FOR SECRETED PROTEINS |
WO2000006728A2 (en) | 1998-07-28 | 2000-02-10 | Incyte Pharmaceuticals, Inc. | Phosphorylation effectors |
WO2000058473A2 (en) | 1999-03-31 | 2000-10-05 | Curagen Corporation | Nucleic acids including open reading frames encoding polypeptides; 'orfx' |
EP1074617A3 (de) | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers für Synthese von ganzen-Länge cDNS und deren Anwendung |
WO2001012659A2 (en) * | 1999-08-18 | 2001-02-22 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Human dna sequences |
EP1572987A4 (de) * | 2000-02-03 | 2005-11-30 | Nuvelo Inc | Neuartige nukleinsäure und polypeptide |
US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
US20020082206A1 (en) * | 2000-05-30 | 2002-06-27 | Leach Martin D. | Novel polynucleotides from atherogenic cells and polypeptides encoded thereby |
AU2002361385B2 (en) | 2001-12-18 | 2009-11-19 | Centre National De La Recherche Scientifique Cnrs | Novel death associated proteins of the THAP family and related Par4 pathways involved in apoptosis control |
CA2507924A1 (en) | 2002-12-10 | 2004-07-01 | Endocube Sas | Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation |
-
2002
- 2002-12-10 AU AU2002361385A patent/AU2002361385B2/en not_active Ceased
- 2002-12-10 WO PCT/EP2002/014027 patent/WO2003051917A2/en active Application Filing
- 2002-12-10 ES ES02796602T patent/ES2337989T3/es not_active Expired - Lifetime
- 2002-12-10 CA CA002471777A patent/CA2471777A1/en not_active Abandoned
- 2002-12-10 JP JP2003552797A patent/JP2005527191A/ja active Pending
- 2002-12-10 EP EP02796602A patent/EP1458754B1/de not_active Expired - Lifetime
- 2002-12-10 US US10/317,832 patent/US7572886B2/en not_active Expired - Fee Related
- 2002-12-10 AT AT02796602T patent/ATE451387T1/de not_active IP Right Cessation
- 2002-12-10 DE DE60234713T patent/DE60234713D1/de not_active Expired - Lifetime
-
2009
- 2009-06-11 US US12/482,790 patent/US20100021482A1/en not_active Abandoned
-
2010
- 2010-02-22 JP JP2010036713A patent/JP2010158248A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2003051917A2 (en) | 2003-06-26 |
EP1458754A2 (de) | 2004-09-22 |
ES2337989T3 (es) | 2010-05-03 |
JP2005527191A (ja) | 2005-09-15 |
ATE451387T1 (de) | 2009-12-15 |
AU2002361385A1 (en) | 2003-06-30 |
AU2002361385B2 (en) | 2009-11-19 |
EP1458754B1 (de) | 2009-12-09 |
CA2471777A1 (en) | 2003-06-26 |
WO2003051917A3 (en) | 2003-12-18 |
JP2010158248A (ja) | 2010-07-22 |
US20030186337A1 (en) | 2003-10-02 |
US20100021482A1 (en) | 2010-01-28 |
US7572886B2 (en) | 2009-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60234713D1 (de) | Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind | |
DE60332239D1 (de) | Neue chemokine bindende peptide, die die biologische aktivität dieser chemokine modulieren | |
CY1111714T1 (el) | Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf). | |
ATE469981T1 (de) | Tests auf proteinkinasen mit fluoreszierenden proteinsubstraten | |
Zampieri et al. | Mechanisms of neurotrophin receptor signalling | |
DE69130828T2 (de) | Statistisch zufällige, pluripotente bio-oligomerenbank, eine methode solche zu synthetisieren und eine methode diese zu benützen | |
DK1049767T3 (da) | En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A) | |
ME00185B (me) | Specifični agensi koji vezuju humani angiopoetin-2 | |
RU2007142191A (ru) | Варианты бета-цепи hgf | |
ATE476495T1 (de) | Bazillus thuringiensis und dessen insektizide proteine | |
CY1111371T1 (el) | Αντισωματα bag3 για χρηση σε ερευνα, διαγνωση και θεραπεια ασθενειων που σχετιζονται με κυτταρικο θανατο | |
ES2168361T3 (es) | Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo. | |
CY1112875T1 (el) | Sfrp και πεπτιδικα μοτιβα που διαντιδρουν με την sfrp και μεθοδοι χρησης τους | |
MXPA02008239A (es) | Gen humano de la esquizofrenia. | |
WO2004029072A3 (en) | PrPsc -INTERACTING MOLECULES AND USES THEREOF | |
DK0948604T3 (da) | Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet | |
BRPI0506148A (pt) | preparação farmacêutica para o tratamento de choque | |
WO2003087138A3 (en) | Methods for identifying polypeptide factors interacting with rna | |
ATE307886T1 (de) | Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung | |
DE50205750D1 (de) | Liganden für den nachweis von prionen | |
ATE349225T1 (de) | Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv | |
ATE301194T1 (de) | Beta-defensine | |
BR9808173A (pt) | Cash (homólogo de caspase) com domìnio efetor de morte, moduladores da função de receptores de fas | |
WO2020198075A3 (en) | Multivalent d-peptidic compounds for target proteins | |
ATE512983T1 (de) | Rezeptor für das tgr3-like protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |